1. Home
  2. AKRO vs ARHS Comparison

AKRO vs ARHS Comparison

Compare AKRO & ARHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • ARHS
  • Stock Information
  • Founded
  • AKRO 2017
  • ARHS 1986
  • Country
  • AKRO United States
  • ARHS United States
  • Employees
  • AKRO N/A
  • ARHS N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • ARHS Other Specialty Stores
  • Sector
  • AKRO Health Care
  • ARHS Consumer Discretionary
  • Exchange
  • AKRO Nasdaq
  • ARHS Nasdaq
  • Market Cap
  • AKRO 2.8B
  • ARHS 1.7B
  • IPO Year
  • AKRO 2019
  • ARHS 2021
  • Fundamental
  • Price
  • AKRO $41.00
  • ARHS $8.21
  • Analyst Decision
  • AKRO Strong Buy
  • ARHS Buy
  • Analyst Count
  • AKRO 9
  • ARHS 12
  • Target Price
  • AKRO $76.29
  • ARHS $12.38
  • AVG Volume (30 Days)
  • AKRO 1.3M
  • ARHS 1.9M
  • Earning Date
  • AKRO 05-09-2025
  • ARHS 05-08-2025
  • Dividend Yield
  • AKRO N/A
  • ARHS N/A
  • EPS Growth
  • AKRO N/A
  • ARHS N/A
  • EPS
  • AKRO N/A
  • ARHS 0.49
  • Revenue
  • AKRO N/A
  • ARHS $1,271,107,000.00
  • Revenue This Year
  • AKRO N/A
  • ARHS $10.22
  • Revenue Next Year
  • AKRO N/A
  • ARHS $8.28
  • P/E Ratio
  • AKRO N/A
  • ARHS $16.69
  • Revenue Growth
  • AKRO N/A
  • ARHS N/A
  • 52 Week Low
  • AKRO $17.86
  • ARHS $6.61
  • 52 Week High
  • AKRO $58.40
  • ARHS $19.81
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 53.64
  • ARHS 48.07
  • Support Level
  • AKRO $36.46
  • ARHS $7.75
  • Resistance Level
  • AKRO $39.59
  • ARHS $8.60
  • Average True Range (ATR)
  • AKRO 2.69
  • ARHS 0.65
  • MACD
  • AKRO 0.69
  • ARHS 0.12
  • Stochastic Oscillator
  • AKRO 93.78
  • ARHS 63.58

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About ARHS Arhaus Inc.

Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in a number of categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and eCommerce sales channels.

Share on Social Networks: